الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 162 |  |  |
| | | from | 162 | | |
Abstract
Metabolic Dysregulation in Patients with Schizophrenia on antipsychotics treatment
Schizophrenia is a severe mental disease, characterized by hallucinations and delusions, negative symptoms, and cognitive dysfunction. Schizophrenia is regarded as a complex syndrome of developmental defects caused by genetic and environmental factors, but the underlying pathological mechanisms are still largely unknown. Schizophrenia patients have a higher mortality rate than the rest of the population, with standardized mortality rates about 2.0. This leads to reduction in life span, estimated to approximately 20 years, which mainly are caused by cardiovascular disease (CVD). An important CVD risk factor is the metabolic syndrome, which has an increased prevalence in schizophrenia that could be due to use of antipsychotic drugs. So, the aim of the present study was to assess metabolic dysregulations in patients with
schizophrenia on antipsychotic treatment. In addition, assess risk factors for developing metabolic dysregulations in patients with schizophrenia on antipsychotics treatment.
A clinical comparative non-randomized cross-sectional study was conducted on 20 patients suffering from schizophrenia and receiving typical antipsychotics only (group I), in addition, 20 patients suffering from Schizophrenia and receiving atypical antipsychotics only (group II). Clinical and laboratory data of the studied groups were tabulated and statistically analyzed.
In this study, it was found that no statistically significant difference between groups typical and atypical antipsychotic regarding demographic data (age, gender, education, job), duration of illness and blood elements (RBCs, HB and PLT). On contrast, there was a significant increase between groups regards number of relapses and WBSc at baseline and after 6 months.
In this study, it was found that, in comparison between baseline and after 6 months, there were no significant differences in both groups regarding lipid profile, albumin, bilirubin and renal function test, but TGs, SGPT and SGOT show significantly different in both groups after 6 months.
In this study, it was found that, there was statistically significant increase in BMI, in both groups and significantly increase in lipid profile in group II.
In this study, it was found that both groups showed mean of blood concentration of plasma triglycerides, total cholesterol, fasting blood sugar, 2 hours’ postprandial blood sugar, HDL and BMI at baseline in the initial visit increased in after 6 months in group I and II. Versus, concentration of HDL which dropped in after 6 months in group I and II.
In the current study, it was found that there was negative correlation in blood elements, lipid profile, Blood sugar, BMI, positive, negative PANSS, liver and renal function regarding number of relapses in group I. while positive correlation in age, age of last, duration of illness and treatment regarding age of onset in group I and II.
In the current study, it was found that there was positive correlation in age and age of last episode regarding duration of illness and treatment in both groups. In addition, positive correlation in blood elements, liver and renal function and blood sugar regarding TG, cholesterol, FBG, 2 hr post prandial BMI in both groups. Also, positive correlation in negative PANSS regarding positive PANSS.